
Death rates from breast cancer are falling faster in Britain than in any of the other six most populous countries …

Eisai has issued a statement to declare their “bewilderment” following a decision from the German Institute for Quality and Efficiency …

Bayer has reported strong financial results for 2014 driven primary by sales of new medicines, although controversy surrounding its anti-clotting …

Boehringer Ingelheim’s tribulations at its US production site Ben Venue Laboratories are refusing to leave as more of its products …

Boehringer Ingelheim has abandoned its hepatitis C (HCV) drug development programme as a dead loss after ‘re-evaluating’ its strategy. The …